Fotemustine, Teniposide and Dexamethasone in Treating Patients with CNS Lymphoma |
Wu, Jing-Jing
(Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University)
Wang, Xin-Hua (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Li, Ling (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Li, Xin (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Zhang, Lei (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Sun, Zhen-Chang (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Fu, Xiao-Rui (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Ma, Wang (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Chang, Yu (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Zhang, Xu-Dong (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Han, Li-Juan (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Zhang, Ming-Zhi (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) |
1 | Van Besien K, Ha CS, Murphy S, et al (1998). Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood, 91, 1178-84. |
2 | Van Tellingen O, Boogerd W, Nooijen WJ, et al (1997). The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue. Cancer Chemother Pharmacol, 40, 330-4. DOI |
3 | Wang X, Song ZF, Xie RM, et al (2013). Analysis of death causes of in-patients with malignant tumors in Sichuan Cancer Hospital of China from 2002 to 2012. Asian Pac J Cancer Prev, 14, 4399-402. 과학기술학회마을 DOI ScienceOn |
4 | Wang XF, Wu YH, Wang MS, et al (2014). CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev, 15, 363-8. 과학기술학회마을 DOI |
5 | Zhu WW, Kang L, Gao YP, et al (2013). Expression level of valosin containing protein is associated with prognosis of primary orbital MALT lymphoma. Asian Pac J Cancer Prev, 14, 6439-43. 과학기술학회마을 DOI |
6 | Zhang J, Zhu MY, Wang L, et al (2013). "Sandwich" chemotherapy (CT) with radiotherapy (RT) improves outcomes in patients with stage IE/IIE extranodal natural killer (NK)/T-cell Lymphomas. Asian Pac J Cancer Prev, 14, 4061-6. DOI ScienceOn |
7 | Zhang ZX, Shen CF, Zou WH, et al (2013). Exploration of molecular mechanisms of diffuse large B-cell lymphoma development using a microarray. Asian Pac J Cancer Prev, 14, 1731-5. 과학기술학회마을 DOI |
8 | Abrey L, DeAngelis LE (2005). CNS lymphomas. Hematal Oncol Clin North Am, 14, 729-38. |
9 | Abrey LE, Yahalom J, DeAngelis LM (2000). Treatment for primary CNS lymphoma: the next step. J Clin Oncol, 18, 3144-50. |
10 | Andres J. M. Ferreri (2011). How I treat primary CNS lymphoma. Blood, 118, 510-22. DOI |
11 | Chen TE (2006). Primary CNS lymphoma. Neurosurg Focus, 5, 21. |
12 | Boehme V, Schmitz N, Zeynalova S, et al (2009). CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood, 113, 3896-902. DOI |
13 | Batchelor T, Carson K, O'Neill A, et al (2003). Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol, 21, 1044-9. DOI ScienceOn |
14 | Bierman P, Giglio P (2005). Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am, 19, 597-609. DOI |
15 | DeAngelis LM, Seiferheld W, Schold SC, et al (2002). Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol, 20, 4643-8. DOI ScienceOn |
16 | FerreriAJ, Abrey LE, Blay JY, et al (2003). Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, J Clin Oncol, 21, 2407-14. DOI ScienceOn |
17 | FerreriAJ, ReniM, ZoldanMC, et al (1996). Importance of complete staging in nonhodgkin's lymphoma presenting as a cerebral mass lesion. Cancer, 77, 827-33. DOI |
18 | FerreriAJ, Blay JY, Reni M, et al (2003). Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol, 21, 266-72. DOI ScienceOn |
19 | G Vassal, I Boland, M J Terrier-Lacombe, et al (1998). Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Clin Cancer Res, 4, 463-8. |
20 | Jin J, Cai L, Liu ZM, et al (2013). miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev, 14, 3681-4. 과학기술학회마을 DOI ScienceOn |
21 | Hoang-Xuan K, Taillandier L, Chinot O, et al (2003). Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol, 21, 2726-31. DOI |
22 | Jellinger KA, Paulus W (1992). Primary central nervous system lymphomas:An update. J Cancer Res Clin Oncol, 119, 7-27. DOI |
23 | Korfel A (2011). Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? Curr Opin Oncol, 23, 436-40. DOI |
24 | Li LF, Wang HQ, Liu XM, et al (2013). Epirubicin inhibits soluble CD25 secretion by Treg cells isolated from diffuse large B-cell lymphoma patients. Asian Pac J Cancer Prev, 14, 1721-4. 과학기술학회마을 DOI |
25 | McAllister LD, Doolittle ND, Guastadisegni PE, et al (2000). Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery, 46, 51-60. |
26 | National Cancer Institute (1988): Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute. |
27 | OBrien P, Roos D, Pratt G, et al (2000) . Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol, 18, 519. |
28 | Mead GM, Bleehen NM, Gregor A, et al (2000). Amedical research council randomized trial in patients with primary cerebral nonhodgkin lymphoma:cerebral radiotherapy with and without cyclophos-phamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer, 89, 1359-70. DOI |
29 | Miller DC, Hochberg FH, Harris NL, et al (1994). Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer, 74, 1383-97. DOI |
30 | Muggia FM (1994). Teniposide: overview of its therapeutic potential in adult cancers. Cancer Chemother Pharmacol, 34, S127-33. DOI |
31 | Omuro AM, Taillandier L, Chinot O et al (2007), Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol, 85, 207-11. DOI ScienceOn |
32 | Reni M, Ferreri AJ, Garancini MP, et al (1997). Therapeutic management of primary central nervous system lymphoma in immunocompetent patients:Results of a critical review of the literature. Ann Oncol, 8, 227-34. DOI ScienceOn |
33 | Rubenstein J, FerreriAJ, Pittaluga S et al (2008). Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma, 49, 43-51. DOI |
34 | Sutcliffe SB, Gospodarowicz MK, Bush RS, et al (1985). Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiother Oncol, 4, 211-23. DOI ScienceOn |
35 | Pels H, Schmidt-Wolf IG, Glasmacher A, et al (2003). Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol, 21, 4489-95. DOI ScienceOn |
36 | Boehme V, Zeynalova S, Kloess M, et al (2007). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol, 18, 149-57. |
37 | Li Q, Yin J, Wang X, et al (2013). B-cell Lymphoma 2 rs17757541 C> G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population. Asian Pac J Cancer Prev, 14, 4301-6. 과학기술학회마을 DOI ScienceOn |